Treasury Regulations · 26 CFR
§ 51.5. Fee calculation.
Regulation text, no changes From the eCFR, current as of October 15, 2026. The eCFR is an authoritative but unofficial editorial compilation of the Code of Federal Regulations; the official text is the annual CFR on govinfo. Compare it with this section on ecfr.gov (external site) or the official annual CFR on govinfo (external site).
Cite as 26 CFR § 51.5
At a glance
Read from the text and its source citation. Not part of the regulation.
- Status
- In the current eCFR
- Issued
- July 28, 2014 by T.D. 9684
- Length
- 1,073 words · about 5 min to read
- Cross-references
- cites 2 Code sections and 0 regulations; cited by 4
¶(a) Fee components—
¶(1) In general. For every fee year, the IRS will calculate a covered entity's total fee as described in this section. The IRS will determine a covered entity's total fee by applying, if applicable, the adjustment amount described in paragraph (e) of this section to the entity's allocated fee described in paragraph (d) of this section.
¶(2) Calculation of branded prescription drug sales. Each covered entity's allocated fee for any fee year is equal to an amount that bears the same ratio to the applicable amount as the covered entity's branded prescription drug sales taken into account during the sales year bears to the aggregate branded prescription drug sales of all covered entities taken into account during the sales year.
¶(3) Applicable amount. The applicable amounts for fee years are—
| Fee year | Applicable amount |
|---|---|
| 2011 | $2,500,000,000 |
| 2012 | 2,800,000,000 |
| 2013 | 2,800,000,000 |
| 2014 | 3,000,000,000 |
| 2015 | 3,000,000,000 |
| 2016 | 3,000,000,000 |
| 2017 | 4,000,000,000 |
| 2018 | 4,100,000,000 |
| 2019 and thereafter | 2,800,000,000 |
¶(4) Sales taken into account. A covered entity's branded prescription drug sales taken into account during any calendar year are as follows:
| Covered entity's branded prescription drug sales during the calendar year that are: | Percentage of branded prescription drug sales taken into account is: |
|---|---|
| Not more than $5,000,000 | 0 |
| More than $5,000,000 but not more than $125,000,000 | 10 |
| More than $125,000,000 but not more than $225,000,000 | 40 |
| More than $225,000,000 but not more than $400,000,000 | 75 |
| More than $400,000,000 | 100 |
¶(b) Determination of branded prescription drug sales. The IRS will compile each covered entity's branded prescription drug sales for each Program by NDC. Each NDC will be attributed to the covered entity identified in the Labeler Code as of the end of the day on December 31st of the sales year. For a covered entity that is a controlled group, this includes all NDCs in which a member of the covered entity is identified. For this purpose, the IRS may revise the list of NDCs as a result of information received in the dispute resolution process, and the data the IRS uses to produce the final fee calculation will include any revisions provided by the Agencies at the completion of the dispute resolution process. Each covered entity's branded prescription drug sales will be reduced by its Medicaid state supplemental rebate amounts in the following manner. If CMS has Medicaid state supplemental rebate information for a sales year, CMS will report to the IRS branded prescription drug sales for Medicaid net of Medicaid state supplemental rebates. If CMS does not have complete Medicaid state supplemental rebate information for a sales year, the IRS will reduce the branded prescription drug sales that CMS reported for Medicaid by Medicaid state supplemental rebates reported by the covered entities on Form 8947.
¶(c) Determination of sales taken into account.
¶(1) For each sales year and for each covered entity, the IRS will calculate sales taken into account. The resulting number is the numerator of the ratio described in paragraph (d)(1) of this section.
¶(2) For each sales year, the IRS will calculate the aggregate branded prescription drug sales taken into account for all covered entities. The resulting number is the denominator of the ratio described in paragraph (d)(2) of this section.
¶(d) Allocated fee calculation. For each covered entity for each fee year, the IRS will calculate the entity's allocated fee by multiplying the applicable amount from paragraph (a)(2) of this section by a fraction—
¶(1) The numerator of which is the covered entity's branded prescription drug sales taken into account during the sales year (described in paragraph (c)(1) of this section); and
¶(2) The denominator of which is the aggregate branded prescription drug sales taken into account for all covered entities during the same year (described in paragraph (c)(2) of this section).
¶(e) Adjustment amount—
¶(1) In general. In addition to the allocated fee computed under paragraph (d) of this section, the IRS will also automatically calculate for each covered entity an adjustment amount. An adjustment amount reflects the difference between the allocated fee determined for the covered entity in the immediately preceding fee year, using data from the second calendar year preceding that fee year, and what the allocated fee would have been for that entity for the immediately preceding fee year using data from the calendar year immediately preceding that fee year. For example, for 2014, the adjustment amount for a covered entity will be the difference between the entity's 2013 allocated fee, using 2011 data, and what the 2013 allocated fee would have been using 2012 data. Although the adjustment reflects a revision of the prior year's fee based on data from the year immediately preceding the prior fee year, the adjustment is only taken into account by adding it to or subtracting it from the allocated fee computed under paragraph (d) of this section for the current fee year to arrive at the total fee for the current fee year. An adjustment amount is treated as a component of the current year's fee. For purposes of section 6601, any increase in the allocated fee computed under paragraph (d) of this section for the current fee year resulting from any adjustment amount, along with the remainder of the fee, is treated as a fee liability due on the due date for the current year's fee. For purposes of sections 6511 and 6611, any adjustment amount that decreases the allocated fee computed under paragraph (d) of this section for the current fee year is treated as a payment towards the current fee liability made on the due date of the current fee year.
¶(2) Amounts paid to a covered entity because of an adjustment amount. If a covered entity's adjustment amount reduces the fee computed under paragraph (d) of this section below zero and results in an amount due to the covered entity for the fee year, the IRS will pay this amount due to the covered entity. A covered entity does not file Form 843, Claim for Refund and Request for Abatement, to receive this amount owed to a covered entity.
[T.D. 9684, 79 FR 43643, July 28, 2014]
Cross-references
Computed from the citations in the text of 26 CFR.
Code sections it cites
- § 6601 Interest on underpayment, nonpayment, or extensions of time for payment, of tax
- § 6511 Limitations on credit or refund
Cited by 4 other regulations
Amendment history
From the source citation at the end of the section, newest first. T.D. is a Treasury decision; FR is the Federal Register.
- Issued by T.D. 9684 (79 FR 43643)
Where it sits in 26 CFR
- Subchapter D Miscellaneous excise taxes
- Part 51 Branded prescription drug fee
Nearby sections
- § 51.1 Overview.
- § 51.2 Explanation of terms.
- § 51.3 Information requested from covered entities.
- § 51.4 Information provided by the agencies.
- § 51.5 Fee calculation.
- § 51.6 Notice of preliminary fee calculation.
- § 51.7 Dispute resolution process.
- § 51.8 Notification and payment of fee.
- § 51.9 Tax treatment of fee.